<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05045963</url>
  </required_header>
  <id_info>
    <org_study_id>2020-0999</org_study_id>
    <secondary_id>NCI-2021-01105</secondary_id>
    <secondary_id>2020-0999</secondary_id>
    <nct_id>NCT05045963</nct_id>
  </id_info>
  <brief_title>Impact of Aminoglycosides in Hypotensive Septic Oncology Patients</brief_title>
  <official_title>Evaluating the Impact of Aminoglycosides in Hypotensive Septic Oncology Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the impact of aminoglycosides in hypotensive septic oncologic patients.&#xD;
      In the oncologic patient population, sepsis is a major health concern due to high mortality&#xD;
      rates and healthcare costs. Prior research shows aminoglycosides antibiotics are frequently&#xD;
      used to treat sepsis, but their clinical impact in hypotensive oncology patients upon the&#xD;
      progression of sepsis is not known.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVE:&#xD;
&#xD;
      I. To assess the impact of beta-lactam (BL) + aminoglycoside (AG) combination therapy in&#xD;
      hypotensive septic oncology patients.&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
      Patients' medical charts are reviewed retrospectively.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 4, 2021</start_date>
  <completion_date type="Anticipated">July 2, 2022</completion_date>
  <primary_completion_date type="Anticipated">July 2, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Time to resolution of hypotension</measure>
    <time_frame>Within 7 days from hypotension onset</time_frame>
    <description>Defined as a mean arterial pressure &gt; 65 mmHg not requiring vasopressors and sustained for &gt;= 24 hours.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">319</enrollment>
  <condition>Hematopoietic and Lymphoid Cell Neoplasm</condition>
  <condition>Malignant Solid Neoplasm</condition>
  <condition>Septicemia</condition>
  <arm_group>
    <arm_group_label>Observational (medical record review)</arm_group_label>
    <description>Patients' medical charts are reviewed retrospectively.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Electronic Health Record Review</intervention_name>
    <description>Medical record reviewed</description>
    <arm_group_label>Observational (medical record review)</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Oncology patients with sepsis and hypotension treated at The University of Texas MD&#xD;
        Anderson Cancer Center from January 1, 2019 to December 31, 2019&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult patients (age &gt;= 18 years) with a diagnosis of sepsis during the index hospital&#xD;
             admission identified by International classification of diseases (ICD)-10 codes (as&#xD;
             specified below) receiving BL antibiotics within 6 hours prior to or following the&#xD;
             onset of hypotension&#xD;
&#xD;
          -  To be included in the AG group, patients must have received at least 1 dose of&#xD;
             intravenous (IV) tobramycin or amikacin in addition to the BL therapy within the above&#xD;
             time period&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age &lt; 18 years&#xD;
&#xD;
          -  Receipt of IV AG outside of the above time frame in the AG group or receipt of IV AG&#xD;
             within 48 hours prior to or following the onset of hypotension in the BL backbone&#xD;
             group&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Patients not receiving therapy with BL antibiotics&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeffrey J Bruno</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>M D Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeffrey J. Bruno</last_name>
      <phone>713-792-0251</phone>
      <email>JJbruno@mdanderson.org</email>
    </contact>
    <investigator>
      <last_name>Jeffrey J. Bruno</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>University of Texas MD Anderson Cancer Center</description>
  </link>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>March 1, 2021</study_first_submitted>
  <study_first_submitted_qc>September 14, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 16, 2021</study_first_posted>
  <last_update_submitted>September 14, 2021</last_update_submitted>
  <last_update_submitted_qc>September 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sepsis</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

